Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 7 4 2013 12 15 1 9 Maryam Taghizadeh Ghehi Research Center for Rational Use of Drugs, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Saeed Rezaee Department of Pharmaceutics, Faculty of Pharmacy, Ahvaz University of Medical Sciences, Ahvaz, Iran. Alireza Hayatshahi Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Molouk Hadjibabaie Research Center for Rational Use of Drugs, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Kheirollah Gholami Research Center for Rational Use of Drugs, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Mohammadreza Javadi Research Center for Rational Use of Drugs, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Seyed Hamid Khoee Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Mania Radfar Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Mohsen Esfandbod Hematology-Oncology and SCT Research Centre, Department of Hematology-Oncology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. Ardeshir Ghavamzadeh Hematology-Oncology and SCT Research Centre, Department of Hematology-Oncology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 2015 10 14 Background: Vancomycin is used abundantly in patients undergoing HSCT, especially during neutropenic fever. Despite its widespread use little is known about vancomycin pharmacokinetics in HSCT patients. We conducted this study to investigate vancomycin pharmacokinetic parameters in our HSCT patients and to evaluate current dosing regimen based on trough vancomycin concentrations measurement. Methods: Vancomycin serum concentration at steady-state was determined prospectively in 46 adult HSCT patients who received vancomycin as empirical treatment of neutropenic fever. Individual steady-steady pharmacokinetic parameters were also determined in 20 patients who had two vancomycin levels from an administered dose, assuming one-compartment model. Acute kidney injury was also evaluated in our patients during vancomycin therapy. Results: Mean (±SD) apparent volume of distribution (L/kg) and clearance (mL/min) were 0.6 (± 0.33) and 109.7 (± 57.5) respectively. With mean (±SD) total daily dose of vancomycin 31.9 (±10.5) mg/kg/day that was administered, more than 90 % of measured vancomycin trough concentrations were outside the range of 15-20 mg/L and 54.3% of patients had trough concentrations below 10 mg/L. Of 46 patients, 21 patients (45.7%) developed acute kidney injury (AKI) during vancomycin therapy; among them 19 patients were receiving nephrotoxic drug(s) concomitantly. Conclusion: Current vancomycin dosage regimen could not lead to recommended therapeutic serum concentrations in our patients. Large variation in vancomycin pharmacokinetic parameters observed among patients of this study along with difference of vancomycin pharmacokinetics in our study and other similar studies further explain the need for therapeutic drug monitoring and individualization of vancomycin dosing. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/443 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/443/354

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 7 4 2013 12 15 10 14 Fahim M Fahim Department of Pediatrics, Assiut University, Assiut 71516, Egypt. Khaled Saad Department of Pediatrics, Assiut University, Assiut 71516, Egypt. Eman A Askar Department of Pediatrics, Assiut University, Assiut 71516, Egypt. Eman Nasr Eldin Department of clinical pathology, Assiut University, Assiut 71516, Egypt. Ahmed F Thabet Department of internal medicine, Assiut University, Assiut 71516, Egypt. 2015 10 14 Aim: the aim of this study is to assess the growth parameters, vitamin D, calcium, and phosphorous status in children with thalassemia major receiving packed red cells transfusion with chelation therapy. Patients and Methods: In a case control study, 100 patients with beta thalassemia major (aged from 4 to 15 years) were compared with 100 sex- and age-matched children serves as a control group. Anthropometric measurement, Serum level of calcium, phosphorus and vitamin D (25 hydroxycholecalciferol) were estimated for all patients & controls. Results: 49% of our patients had short stature. 47% were underweight. BMI of 43 (43%) patients were low. The mean total serum calcium (6.6±1.2 mg/dl) and 25-hydroxycholecalciferol (25-OH Vit D) (10.4±4.6 mcg/dl) levels were significantly lower in our patients than in controls (10.2±1.06 mg/dl and 40.2±12.3 mcg/dl, respectively); each P< 0.001. Conclusion: Children with beta thalassemia major have delayed growth and metabolic abnormalities that signify the importance of therapeutic interventions. The presence of these abnormalities may be due to iron overload and poor nutritional support. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/442 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/442/355

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 7 4 2013 12 15 15 23 Khushnuma Cooper Regenerative Medicine Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Rd. Rabale, Navi Mumbai - 400701, Maharashtra, India. Viru Shah Regenerative Medicine Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Rd. Rabale, Navi Mumbai - 400701, Maharashtra, India. Nupur Sapre Regenerative Medicine Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Rd. Rabale, Navi Mumbai - 400701, Maharashtra, India. Ekta Sharma Regenerative Medicine Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Rd. Rabale, Navi Mumbai - 400701, Maharashtra, India. Chetna Mistry Regenerative Medicine Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Rd. Rabale, Navi Mumbai - 400701, Maharashtra, India. Chandra Viswanathan Regenerative Medicine Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Rd. Rabale, Navi Mumbai - 400701, Maharashtra, India. 2015 10 14 Background: Umbilical cord tissue is a very rich source of mesenchymal stem cells. Instead of discarding this source we are banking the tissue along with cord blood for possible future cell based applications. The cord tissue needs to be transported and stored properly in order for it to be good enough for cell isolation at a later date. In this paper we have carried out a validation study to determine the maximum permissible time between cord tissue collection and beginning of cell culture process under defined conditions of temperature and collection media. Methods: Ten cord tissue samples were used for this study. The umbilical cord tissue segments were transported and stored at 2 – 8oC for varying periods of time viz. 04, 11, 22 and 30 days in a defined medium after which MSCs were isolated and characterized by flow cytometry. Karyotypic studies were also performed on the isolated cells at the above time points. Results: MSCs could be successfully isolated from 09 even samples after a storage period of 22 days and from 07 samples after a period of 30 days from the date of collection. There was no change in the morphology, immunophenotye, karyotypye and growth potential of the cells isolated from cord tissue after the maximum storage period of 30 days. Conclusion: The umbilical cord tissue is stable for as long as 22 days if stored at the recommended storage conditions of 2 – 8oC in the defined medium. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/441 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/441/356

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 7 4 2013 12 15 24 28 Ali Basi Assistant professor of Medical Oncology and Hematology, Iran University of Medical Sciences (IUMS), Tehran, Iran. Shahab Sohrabkhani Internist, Iran University of Medical Sciences (IUMS), Tehran, Iran. Farhad Zamani Associated professor of Gastroenterology, Gastrointestinal and Liver Disease Research Center (GILDRC), Iran University of Medical Sciences (IUMS), Tehran, Iran. Massoud Baghai-Wadji Associated professor of Surgery, Iran University of Medical Sciences (IUMS), Tehran, Iran. Neda Rabiei Resident of internal Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran. Seyyed Razavi Assistant professor of Medical Oncology and Hematology, Iran University of Medical Sciences (IUMS), Tehran, Iran. Hossein Ajdarkosh Assistant professor of Gastroenterology, Gastrointestinal and Liver Disease Research Center (GILDRC), Iran University of Medical Sciences (IUMS), Tehran, Iran. 2015 10 14 Background: Recent researches have led to find strategies to prevent relapse and to improve survival for gastric cancer patients, including preoperative neo-adjuvant approaches. However, the efficacy of some neo-adjuvant regimens including 5-fluorouracil, cisplatin, and docetaxel have been less investigated. The present study evaluated the outcome and mid-term survival of patients with gastric cancer who undergoing this regimen. Methods: In a randomized double-blinded controlled trial performed at the Firoozgar hospital in Tehran in 2011-12, 61 patients were randomly assigned to treatment (32 to neo-adjuvant chemotherapy with docetaxel, cisplatin and 5-fluorouracil (5-FU) before surgery and 27 to surgery alone). The present study tried to assess the efficacy of neoadjuvant chemotherapy regarding improvement of mid-term survival, complications, and R0 resection status. Results: The two groups were matched in terms of gender, mean age, cancer location, and TNM staging. However, R0 resection in the former group was 85.7%; while this indicator in the isolated surgery group was significantly lower (61.5%). Regarding WHO performance, no significant difference was observed across the two groups. Patients in neo-adjuvant chemotherapy group were followed for mean follow-up time 10.32 months and those who categorized in isolated surgery group were followed for mean follow-up time 10.88 months. Mid-term mortality rate in the two groups was 14.3% and 15.4%, respectively (p = 0.866). In this regard, 3-, 6-, and 9-month survival rate in neo-adjuvant chemotherapy group was 96.4%, 89.3%, and 85.7%, respectively. These survival rates in the surgery group were 92.3%, 88.5%, and 84.6%, respectively. Multivariable logistic regression analysis showed that among all study variables, only R0 resection status could predict mid-term mortality. Conclusion: Neo-adjuvant chemotherapy and surgery compare to surgery alone more improve R0 resection status, but mid-term survival rate is similar in the two regiments. R0 resection status can effectively predict appropriate mid-term survival in undertreated patients. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/440 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/440/357

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 7 4 2013 12 15 29 33 Dariyush Raeisi Department of nephrology, Kermanshah University of Medical Science, Kermanshah, Iran. Mehrdad Payandeh Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. Seyed Hamid Madani Department of Pathology, Kermanshah University of Medical Science, Kermanshah, Iran. Mohammad Erfan Zare Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. AND Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. Atefeh Nasir Kansestani Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. Amir Hossein Hashemian Research Center for Environmental Determinants of Health (RCEDH), Kermanshah University of Medical Sciences, Kermanshah, Iran. AND Department of Biostatistics and Epidemiology, Kermanshah University of Medical Sciences, School of Public Health, Kermanshah, Iran. 2015 10 14 Introduction: The long-term use of immunosuppressive agents for prevention of allograft rejection increases the risk of malignancy approximately 100 times as high as that in the general population and Kaposi’s sarcoma (KS) is a relatively common malignancy after kidney transplantation. The aim of present study was to investigate the frequency of KS in patients with kidney transplantation in 20 years period. Material and methods: In this study Charts and pathology reports of 1487 recipients for kidney allografts treated at Imam Reza hospital between 1991 and 2012 were reviewed. The SPSS software package version 16 (SPSS Inc., Chicago, Illinois, USA) was used for the statistical analysis. Results: There were 17 of 1487 incident cases of KS kidney transplant population at our hospital in period of study. There is no significant difference between age and gender of patients. The mean time between transplantation and non-KS malignant tumors was 34.4 ± 21.8 months (range 12–140 months), while in KS patients it was 18.7 ± 25.2 months, which was statistically significantly different (P < 0.05). After detection of KS in 12 patients, we perform serum antibody detection against HHV. Among them, 8 (66.6%) were seropositive. Conclusion: KS is a common long-term complication in renal transplant recipients, with an increased incidence compared with the general population. Given that candidates for organ transplantation who are seropositive for HHV-8 -and thus at risk for KS- can now be identified, chemoprevention should be available in this high-risk population. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/439 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/439/358

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 7 4 2013 12 15 34 39 Akbar Dorgalaleh Hematology Department, Allied Medical School, Tehran University of Medical Sciences, Tehran, Iran. Mohammad Mahmudi Pars Pathobiology laboratory, Minoodasht, Golestan, Iran. Shadi Tabibian Hematology Department, Allied Medical School, Tehran University of Medical S unrelated donors and recipients for HLA-A, -B and -DRB1 loci is a prediction for an improved outcome. Methods and materials: HLA-A and -B of six hundred Iranian cord blood samples were typed by PCR-SSP method and the frequency of loci were estimated. Results: The most frequent alleles were A*02(18.16), A*24(16.41), B*35(21.66) and B*51(13.35), respectively. Discussion: Our HLA typing data show similarity between neighbor and related countries and Caucasians. Identifying HLA alleles helps to find suitable donors for patients in need of hematopoietic stem cell transplantation. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/211 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/211/204

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 3 2 2009 06 15 21 26 Kamran Alimoghaddam Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran L Moezzi Faculty of Paramedical Sciences, Tehran University of Medical Sciences, Tehran, Iran Hamid Ghaffari Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran Alireza Arjmand Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran P Ghodsi Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran Bahram Chahardouli Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran S Shahrokhi Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran Ardeshir Ghavamzadeh Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran 2015 10 01 Introduction: Hematopoietic stem cells are always in a quiescence state. Since they need retroviral transduction to infect dividing cells, they are resistant to retrovirus transduction. They need to be pre-stimulated by a cytokine cocktail. For proliferation without maturation, we suggest MIP-1α as a novel factor. Material and methods: Retroviral vector produced by PG13/LN C8 cells titter on Hela cells. Then, the CD34+ cells of cord blood can be pre-stimulated in a serum- free media supplemented with SCF, Flt3,TPO,IL6 in the presence and absence of 50 ng/ml MIP-1α. Transduction efficiency was assessed by a semi-quantitative PCR for the neomycin gene. Results: A PCR analysis of the neomycin gene in CD34+ cells revealed an improved transduction of cord blood cells in the presence of MIP-1α 65%, in comparison to its absence: 40.7%. Conclusion: the addition of MIP-1α to the cytokine cocktail improves the transduction efficiency of cord blood hematopoietic progenitor cells. Further studies are required to clarify its effect on the functional properties of CD34+ cells. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/212 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/212/205

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 3 2 2009 06 15 27 30 Shahrbanou Keyhanian Oncology- Hematology Department, School of Medicine, Islamic Azad University, Tonekabon, Mazandaran, Iran O Taziki Nephrology Department, Medical University of Mazandaran MM Saravi Radiology Department, Imam Sajjad Hospital, Ramsar, Mazandaran, Iran Z Fotokian School of Nursing and Midwifery, Ramsar, Babol Medical Sciences university, Mazandaran, Iran 2015 10 01 Introduction: Chemotherapeutic drugs used to treat cancer may cause nausea and emesis by inducing the release of 5-hydroxytryptamine (5-HT) in the small intestine. Blockage of 5-HT3 receptors in the small intestine by 5-HT3 receptor antagonists might prevent the nausea and vomiting associated with chemotherapy for cancer. The aim of this study was to compare the efficacy and tolerability of the 5-HT3 receptor antagonists (granisetron) and granisetron plus dexamethasone in the treatment of acute chemotherapy induced digestive emesis and nausea. Materials and Methods: Patients on their first course of emetic chemotherapy (cisplation or doxorubicin based regimen) were randomly placed into two treatment groups. Group A received a one-time administration of granisetron 3 mg, IV and group B received granisetron plus dexamethasone 8 mg IV. For each study the drug were administered one time, 30 minutes before infusion of chemotherapy emetic agent. For the efficacy assessment, response data were recorded every 6 hours for a total of 24 hours, after the start of the chemotherapy infusion. Results: A total of 138 patients [86 males, 52 females with amean age of 48 (a range between 15-82 years)] were involved in the study . Of these, 125 were evaluable. Discussion: The ability of granisetron plus dexamethason to prevent acute emesis was significantly better than, administering granisetron alone (66.7% vs 42.8% respectively) (p<0.001). The combination of granisetron and low-dose dexamethasone is superior to granisetron alone to control acute emetic episodes in patients receiving emetogenic chemotherapy. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/213 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/213/206

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 3 2 2009 06 15 31 32<